Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Sangsang Tang"'
Autor:
Lele Ye, Xinya Tong, Kan Pan, Xinyu Shi, Binbing Xu, Xuyang Yao, Linpei Zhuo, Su Fang, Sangsang Tang, Zhuofeng Jiang, Xiangyang Xue, Weiguo Lu, Gangqiang Guo
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundSerous ovarian carcinoma (SOC) is considered the most lethal gynecological malignancy. The current lack of reliable prognostic biomarkers for SOC reduces the efficacy of predictive, preventive, and personalized medicine (PPPM/3PM) in patien
Externí odkaz:
https://doaj.org/article/37fbb6c0ce474e2eaa0c14d5e3b121d9
Autor:
Fang Zheng, Jiamin Zhong, Kelie Chen, Yu Shi, Fang Wang, Shengchao Wang, Song Tang, Xiaoyu Yuan, Zhangjin Shen, Sangsang Tang, Dajing Xia, Yihua Wu, Weiguo Lu
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-21 (2023)
Abstract Background Ovarian cancer is commonly associated with a poor prognosis due to metastasis and chemoresistance. PINK1 (PTEN-induced kinase 1) is a serine/threonine kinase that plays a crucial part in regulating various physiological and pathop
Externí odkaz:
https://doaj.org/article/16cde446b6a34c42b1903a7c67b2df9d
Publikováno v:
Cell Death and Disease, Vol 13, Iss 9, Pp 1-14 (2022)
Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors are efficacious in treating platinum-sensitive ovarian cancer (OC), but demonstrate limited efficiency in patients with platinum-resistant OC. Thus, further investigations into combined strategi
Externí odkaz:
https://doaj.org/article/7d21a15fc0d747189920e26c5a19a03b
Autor:
Yangyang Li, Yixuan Cen, Mengyan Tu, Zhenzhen Xiang, Sangsang Tang, Weiguo Lu, Hongbo Zhang, Junfen Xu
Publikováno v:
Research, Vol 6 (2023)
Platinum-based chemotherapy remains the main systemic treatment of ovarian cancer (OC). However, the inevitable development of platinum and poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) resistance is associated with poor outcomes,
Externí odkaz:
https://doaj.org/article/86b8a0d90dec484ea32eff84cb9c957c
Autor:
Junfen Xu, Yuanming Shen, Conghui Wang, Sangsang Tang, Shiyuan Hong, Weiguo Lu, Xing Xie, Xiaodong Cheng
Publikováno v:
Cell Death Discovery, Vol 7, Iss 1, Pp 1-9 (2021)
Abstract The poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors show survival benefits in ovarian cancer patients with BRCA1/2 mutation or homologous recombination (HR) deficiency, but only limited efficacy in HR-proficient ones. Another
Externí odkaz:
https://doaj.org/article/170f485243834593b335a1d6d286f515
Autor:
Lele Ye, Kan Pan, Su Fang, Su-Ni Wu, Su Chen, Sangsang Tang, Nan Wang, Haoke Zhang, Xinya Tong, Xinyu Shi, Shiyu Feng, Dan Xiang, Ruanmin Zou, Yingying Hu, Xiangyang Xue, Gangqiang Guo
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Serous ovarian carcinoma (SOC) is a gynecological malignancy with high mortality rates. Currently, there is a lack of reliable biomarkers for accurate SOC patient prognosis. Here, we analyzed SOC RNA-Seq data from The Cancer Genome Atlas (TCGA) to id
Externí odkaz:
https://doaj.org/article/d3610c8cf0b945cca215e0f362eb1a73
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
ObjectivesTo evaluate whether the modified intraperitoneal plus intravenous chemotherapy regimen as a first-line therapy for advanced epithelial ovarian cancer (EOC) in China can be well-tolerated or confer any potential benefit on survival.MethodsWe
Externí odkaz:
https://doaj.org/article/3b7bd69618014298afa2520d790916f0
Autor:
Zhangjin Shen, Lingkai Gu, Yuwan Liu, Lingfang Wang, Jiawei Zhu, Sangsang Tang, Xinyi Wei, Jiaying Wang, Songfa Zhang, Xinyu Wang, Xiaodong Cheng, Xing Xie, Weiguo Lu
Publikováno v:
Oncogene. 41:4145-4158
Wide metastasis contributes to a high death rate in ovarian cancer, and understanding of the molecular mechanism helps to find effective targets for metastatic ovarian cancer therapy. It has been found that phospholipase A2-activating protein (PLAA)
Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer
Autor:
Junfen Xu, Yifeng Fang, Kelie Chen, Sen Li, Sangsang Tang, Yan Ren, Yixuan Cen, Weidong Fei, Bo Zhang, Yuanming Shen, Weiguo Lu
Publikováno v:
Clinical Cancer Research. 28:3590-3602
Purpose: The heterogeneity of high-grade serous ovarian cancer (HGSOC) is not well studied, which severely hinders clinical treatment of HGSOC. Thus, it is necessary to characterize the heterogeneity of HGSOC within its tumor microenvironment (TME).
Autor:
Weiguo Lu, Yuanming Shen, Bo Zhang, Weidong Fei, Yixuan Cen, Yan Ren, Sangsang Tang, Sen Li, Kelie Chen, Yifeng Fang, Junfen Xu
Purpose:The heterogeneity of high-grade serous ovarian cancer (HGSOC) is not well studied, which severely hinders clinical treatment of HGSOC. Thus, it is necessary to characterize the heterogeneity of HGSOC within its tumor microenvironment (TME).Ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5fa1a7aa150109dcdf90b91e3c8da5c
https://doi.org/10.1158/1078-0432.c.6532386.v1
https://doi.org/10.1158/1078-0432.c.6532386.v1